|
Atrial Fibrillation
|
0.410 |
AlteredExpression
|
disease |
BEFREE |
In patients with AF, Fn14 protein levels were higher in atrial myocytes from atrial appendages, and expression of TWEAK was increased in peripheral blood mononuclear cells, while TWEAK serum levels were decreased.
|
29971943 |
2018 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Moreover, an anti-Fn14 mAb that blocks TWEAK-Fn14 interaction could totally abrogate TWEAK binding and TWEAK-induced cell death in all TWEAK-sensitive tumor cell lines.
|
12496418 |
2003 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
This was further supported by decreased gene expression of extracellular matrix-degrading proteases (uPA, PLAT, ADAM8), cell adhesion molecules (integrins, laminins), pro-inflammatory mediators of the metastasis-promoting tumor microenvironment (TNFSF12, IL6, ANGPTL2, CSF1R) and concomitant increased expression of the validated breast cancer metastasis suppressor gene (BRMS1).
|
24498382 |
2014 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The TWEAK:Fn14 signaling axis promotes tumor cell proliferation and tumor angiogenesis, while TRAIL:TRAIL-receptor (TRAIL-R) interactions selectively induce apoptosis in malignant cells.
|
24130833 |
2013 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
The TNF-like weak inducer of apoptosis (TWEAK; TNFSF12) receptor Fn14 (TNFRSF12A) is expressed at low levels in normal tissues but frequently highly expressed in a wide range of tumor types such as lung, melanoma, and breast, and therefore it is a potentially unique therapeutic target for these diverse tumor types.
|
23722548 |
2013 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Pharmacokinetics of RG7212 and dynamics of TWEAK were determined, as were changes in tumor TWEAK-Fn14 signaling in paired pre- and posttreatment tumor biopsies.
|
26446946 |
2016 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Both GrB-TWEAK and GrB-Fc-IT4 displayed significant tumor growth inhibition when administered to mice bearing orthotopic MDA-MB-231 (TNBC) tumor xenografts.
|
25239934 |
2014 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
These factors and TWEAK-induced signaling were decreased, and tumor, blood, and spleen immune cell composition was altered with RG7212 treatment in mice.
|
23974006 |
2013 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
TWEAK, a new member of the tumor necrosis factor (TNF) family, induces cell death in some tumor cell lines, but its physiological functions are largely unknown.
|
11067885 |
2000 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
As malignant cell apoptosis is strongly enhanced by secondary oligomerization of TRAIL, we tested the hypothesis that soluble Fn14·TRAIL can be oligomerized and become more active by adding TWEAK, a cytokine secreted in the tumor environment.
|
28455246 |
2017 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Using two different approaches, genetic deletion of TNFSF12 and treatment with a TWEAK blocking mAb in atherosclerosis-prone mice, we have analysed the effect of TWEAK inhibition on atherosclerotic plaques progression and stability.
|
24479820 |
2014 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Soluble TWEAK serum concentration was measured in 702 CKD patients without any previous CV event from The National Observatory of Atherosclerosis in Nephrology (NEFRONA) Study.
|
28390291 |
2017 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results suggest that TWEAK is involved in atherosclerosis by inducing pro-inflammatory cytokines and extracellular matrix degrading enzymes, which reduce plaque stability.
|
15056843 |
2004 |
|
Arteriosclerosis
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
Genetic inactivation of Tnfsf12 reduced atherosclerosis extension and severity in diabetic ApoE deficient mice.
|
28447667 |
2017 |
|
Atherosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Soluble TWEAK serum concentration was measured in 702 CKD patients without any previous CV event from The National Observatory of Atherosclerosis in Nephrology (NEFRONA) Study.
|
28390291 |
2017 |
|
Atherosclerosis
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
Genetic inactivation of Tnfsf12 reduced atherosclerosis extension and severity in diabetic ApoE deficient mice.
|
28447667 |
2017 |
|
Atherosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Using two different approaches, genetic deletion of TNFSF12 and treatment with a TWEAK blocking mAb in atherosclerosis-prone mice, we have analysed the effect of TWEAK inhibition on atherosclerotic plaques progression and stability.
|
24479820 |
2014 |
|
Atherosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results suggest that TWEAK is involved in atherosclerosis by inducing pro-inflammatory cytokines and extracellular matrix degrading enzymes, which reduce plaque stability.
|
15056843 |
2004 |
|
Kidney Failure, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
Bcl3 was the top upregulated NF-κB-related gene in experimental AKI and one of the most upregulated genes in TWEAK-stimulated tubular cells.
|
28684863 |
2017 |
|
Kidney Failure, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
Nilotinib ameliorates folic acid-induced acute kidney injury through modulation of TWEAK and HSP-70 pathways.
|
31593741 |
2019 |
|
Kidney Failure, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
Multiple stimuli activate NF-kappaB through the classical pathway in somatic renal cells, and noncanonical pathway activation by TWEAK occurs in acute kidney injury.
|
20651166 |
2010 |
|
Kidney Failure, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
We have now explored the cell death pathways induced by TWEAK/Fn14 activation and their relevance during AKI.
|
29588419 |
2018 |
|
Lupus Nephritis
|
0.040 |
Biomarker
|
disease |
BEFREE |
By reviewing the literature, this article assesses the role of this pathway in lupus nephritis, underlines the importance of TWEAK in urine (uTWEAK) as a biomarker of the disease and stresses the favourable results published in the literature from the inhibition of the TWEAK/Fn14 pathway as a therapeutic target in experimental animal models, demonstrating its potential application in other settings.
|
27595519 |
2018 |
|
Lupus Nephritis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Combined utilization of untimed single urine of MCP-1 and TWEAK as a potential indicator for proteinuria in lupus nephritis: A case-control study.
|
29668584 |
2018 |
|
Lupus Nephritis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Some ongoing trials explore novel concepts derived from models, such TWEAK targeting as tissue protection for lupus nephritis.
|
25814248 |
2015 |